Clinical trial · Interventional
Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer
Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer：A Phase 2, Randomized Controlled Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to learn whether new adjuvant radiotherapy with gross tumor volume(GTV) escalated to 58.75 Gy can improve complete response (CR) rates compared with GTV dose of 50 Gy in adult patients (18-79 years) with locally advanced rectal adenocarcinoma (T3-T4/N+, M0) located ≤10 cm from the anal verge.The main questions it aims to answer are: 1. Does GTV simultaneously boost to 58.75 Gy/25f increase complete response (pCR or cCR) compared with 50 Gy/25f? 2. How do the two regimens differ in terms of progression-free survival (PFS), pelvic local control (LC), tumor regression grade (TRG), organ preservation, and treatment-related toxicity? Researchers will compare GTV 58.75 Gy/25f (experimental arm) versus GTV 50 Gy/25f (control arm) to see if dose escalation improves tumor response rate. Participants will: 1. Receive neoadjuvant radiotherapy with one of the two PGTV dose escalated regimens (with concurrent chemotherapy: oral capecitabine or XELOX). 2. Undergo restaging with imaging and clinical assessment before surgery or observation. 3. Proceed to total mesorectal excision (TME), local excision, or "watch-and-wait" strategy depending on treatment response and patient preference. 4. Be followed regularly with clinical exams, imaging, endoscopy, and laboratory tests to assess efficacy, safety, and long-term outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Rectal Adenocarcinoma | Rectal Adenocarcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Concurrent Chemotherapy | Drug | — | UNRESOLVED |
| GTV 50 Gy/25 fractions(Simultaneous Integrated Boost) | Radiation | — | UNRESOLVED |
| GTV 58.75 Gy/25 fractions(Simultaneous Integrated Boost) | Radiation | — | UNRESOLVED |
| Total mesorectal excision (TME) surgery or non-operative management | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Experimental Arm (GTV 58.75 Gy/25f)
- description
- Radiotherapy: long course simultaneous integrated boost radiotherapy * Gross tumor volume (GTV): A total dose of 58.75Gy delivered in 25 fractions using a simultaneous integrated boost approach. * CTV: 45Gy/25f * Mesorectum lymph node(GTVnd1):58.75Gy/25f * Lateral lymph node（GTVnd2）：60Gy/25f Concurrent Chemotherapy: Concurrent administration of capecitabine (825 mg/m² twice daily, 5 days per week) or XELOX regimen during radiotherapy After treatment, patients will undergo restaging and proceed to total mesorectal excision (TME) or non-operative management ("watch-and-wait") depending on response and clinical assessment.
- interventionNames
- Radiation: GTV 58.75 Gy/25 fractions(Simultaneous Integrated Boost)
- Drug: Concurrent Chemotherapy
- Procedure: Total mesorectal excision (TME) surgery or non-operative management
- type
- ACTIVE_COMPARATOR
- label
- Control Arm (PGTV 50 Gy/25f)
- description
- Radiotherapy: long course simultaneous integrated boost radiotherapy Gross tumor volume (GTV): A total dose of 50Gy delivered in 25 fractions using a simultaneous integrated boost approach. CTV: 45Gy/25f Mesorectum lymph node(GTVnd1):58.75Gy/25f Lateral lymph node（GTVnd2）：60Gy/25f Concurrent Chemotherapy: Concurrent administration of capecitabine (825 mg/m² twice daily, 5 days per week) or XELOX regimen during radiotherapy After treatment, patients will undergo restaging and proceed to total mesorectal excision (TME) or non-operative management ("watch-and-wait") depending on response and clinical assessment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥18 and \<80 years 2. Histologically confirmed rectal adenocarcinoma 3. Tumor located within 10 cm from the anal verge 4. MRI staging: T3-T4 and/or N+, M0 (AJCC 8th edition) 5. ECOG performance status 0-2 6. Adequate bone marrow function: WBC ≥3×10⁹/L, ANC ≥1.5×10⁹/L, PLT ≥100×10⁹/L, Hb ≥90 g/L 7. Adequate liver function: TBIL ≤1.5 × ULN, ALT/AST ≤2.5 × ULN 8. Adequate renal function: Cr ≤1.5 × ULN or CCr ≥60 mL/min 9. Signed informed consent Exclusion Criteria: 1. Prior rectal cancer surgery 2. Prior induction chemotherapy, immunotherapy, or pelvic radiotherapy 3. History of other malignancies 4. History of chronic colitis, ulcerative colitis, or nonspecific proctitis 5. Pregnant or breastfeeding women 6. Active infection or fever 7. Severe uncontrolled comorbidities (e.g., unstable heart disease, renal disease, chronic hepatitis, uncontrolled diabetes, psychiatric disorders) 8. Inability to comply with study protocol
References
Publications (0)
Data not yet available